Biofrontera, a German VC-backed biotech company, is preparing to list on Prime Standard of the Frankfurt Stock Exchange. The company’s main shareholder is Heidelberg Innovation, which owns 43% of the business. Other investors, which together own 20%, include DNAPrint genomics Inc, LeVenture Kapitalbeteiligungsgesellschaft, TechnoMedia Kapitalbeteiligungsgesellschaft Köln, Pricap and TRE Holding.
Founded in 1997 and receiving its first investment that same year, Biofrontera is a specialty pharma company focusing on dermatology and inflammation-induced diseases and has three dermatological projects in Phase II clinical trials.
Since 1997 it has raised €27.4m from investors and €8m in grants from federal and state governments and the European Union.